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The molecular mechanisms underlying atrial fibrillation, the most
common sustained cardiac arrhythmia, remain poorly understood.
Genome-wide association studies uncovered a major atrial fibril-
lation susceptibility locus on human chromosome 4q25 in close
proximity to the paired-like homeodomain transcription factor 2
(Pitx2) homeobox gene. Pitx2, a target of the left-sided Nodal
signaling pathway that initiates early in development, represses
the sinoatrial node program and pacemaker activity on the left side.
To address the mechanisms underlying this repressive activity, we
hypothesized that Pitx2 regulates microRNAs (miRs) to repress the
sinoatrial node genetic program. MiRs are small noncoding RNAs that
regulate gene expression posttranscriptionally. Using an integrated
genomic approach, we discovered that Pitx2 positively regulates
miR-17-92 and miR-106b-25. Intracardiac electrical stimulation
revealed that both miR-17-92 and miR-106b-25 deficient mice ex-
hibit pacing-induced atrial fibrillation. Furthermore electrocardio-
gram telemetry revealed that mice with miR-17-92 cardiac-specific
inactivation develop prolonged PR intervals whereas mice with
miR-17-92 cardiac-specific inactivation and miR-106b-25 heterozy-
gosity develop sinoatrial node dysfunction. Both arrhythmias are
risk factors for atrial fibrillation in humans. Importantly,miR-17-92
andmiR-106b-25 directly repress genes, such as Shox2 and Tbx3, that
are required for sinoatrial node development. Together, to our know-
ledge, these findings provide the first genetic evidence for an miR
loss-of-function that increases atrial fibrillation susceptibility.
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Atrial fibrillation (AF), the most common arrhythmia in adultpatients, increases in prevalence with age to almost 5% of the
population over 65. Patients with AF have an increased risk of
stroke, dementia, and heart failure (1). Electrical impulses that
are critical for a coordinated, physiologic heartbeat originate in
the sinoatrial node (SAN). In AF, abnormal fibrillatory atrial
impulses override normal SAN function, with resultant irregular
conduction to the ventricles. Many cases of ectopic electrical ac-
tivity originate in the pulmonary vein (2). Other sites of ectopy
include the left atrial posterior wall, superior vena cava, interatrial
septum, crista terminalis, and coronary sinus myocardium (3, 4).
Multiple approaches have been used to uncover genes that
may contribute to the AF phenotype in adult patients. A sem-
inal genome-wide association study (GWAS), subsequently repli-
cated by multiple studies, uncovered a single nucleotide variant
(SNV) on human 4q25 that was strongly associated with familial
AF (5). Patients with the 4q25 variant exhibited early onset AF
that was independent from other risk factors such as hyper-
tension and diabetes, suggesting a novel biologic mechanism
involving genes located on chromosome 4q25. The presence of
the 4q25 SNV also had prognostic value because patients with
the SNV are prone to cardioembolic stroke and AF recurrence
after ablation therapy (6, 7).
MicroRNAs (miRs) are 21- to 25-nucleotide noncoding RNAs
that function in biologic processes by posttranscriptional gene si-
lencing (8, 9). Mouse studies have revealed multiple roles for miRs
in heart development (9, 10). MiR-17-92 and its two homologous
clusters, miR-106a-363 and miR-106b-25, encode polycistronic
miRs that are processed from a common primary miR and are
grouped into different families based on their seed sequences
(Fig. S1A) (11, 12). Germ-line miR-17-92 loss-of-function
results in heart defects including ventricular septal defects that
result from abnormal differentiation of second heart field car-
diac progenitors (13, 14).
Paired-like homeodomain transcription factor 2 (Pitx2) is the
gene in closest proximity to the 4q25 SNV that has biologic rele-
vance for AF (5). Pitx2 is expressed on the left side of multiple
organ primordia and mature organs including the heart. Within the
developing heart, Pitx2 is highly expressed in multiple sites that are
prone to ectopic electrical activity, such as the left atrium, pulmo-
nary vein, interatrial septum, crista terminalis, and left caval vein
myocardium (15, 16). Pitx2 haploinsufficient (Pitx2null/+) adult
mice are prone to AF under intracardiac electrical stimulation,
revealing a direct functional connection between AF and reduced
Pitx2 levels (16, 17).
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Atrial Fibrillation (AF) is the most common sustained cardiac ar-
rhythmia in the human population. It is critical to elucidate the
molecular mechanisms underlying AF, given that the prevalence
of AF is expected to dramatically increase as the human pop-
ulation ages. We identified a microRNA (miR)-regulated genetic
pathway that delimits sinoatrial node development and inhib-
its AF. To our knowledge, our data are the first genetic evi-
dence showing that miR deletion results in AF predisposition.
Moreover, to our knowledge, our data are the first demon-
stration that sinoatrial node regulatory genes are regulated by
miRs. Our findings suggest attractive therapeutic targets to
treat AF given that miR-based therapeutics are feasible using
miR antagonists and mimics.
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Here, we discovered that miR-17-92 and miR-106b-25 are
novel downstream Pitx2 target genes and are AF susceptibility
genes. MiR-17-92 and miR-106b-25 inhibit the SAN genetic
program in the coronary sinus and left atrium. To our knowl-
edge, our findings are the first genetic evidence that miRs reg-
ulate SAN development and are implicated in AF predisposition.
Results
Pitx2 Positively RegulatesmiR-17-92 andmiR-106b-25. To gain insight
into miRs involved in AF pathogenesis, we performed miR ex-
pression profiling using hearts from Pitx2null/null mutant and wild
type, and ChIP-sequencing (ChIP-Seq) using hearts from the Pitx2-
Flag allele (16, 18), which express Pitx2 with a C-terminal Flag
epitope tag (Fig. 1 A and C). The miR profiling data at embryonic
day 13.5 (E13.5) reveal that multiple individual miRs encoded by
miR-17-92 and miR-106b-25 are reduced in Pitx2null/null mutant
hearts (Fig. 1A). These findings are further confirmed by real-
time RT-PCR (Fig. 1B). ChIP-Seq analysis using chromatin from
adult mouse heart of the Pitx2Flag allele (GEO accession no.
GSE50401) (18) revealed that Pitx2 directly binds conserved
chromatin upstream of miR-17-92 and miR-106b-25 (Fig. 1C).
The Pitx2-occupied chromatin also are DNase I hypersensitive
sites (ENCODE, 8-wk heart) and are occupied by p300 (ChIP-
Seq data from GEO accession no. GSE32587) (19), suggesting
Pitx2 actively regulates miR-17-92 and miR-106b-25. The Pitx2
binding regions were further confirmed by real-time PCR using
E13.5 Pitx2-Flag mouse heart ChIP chromatin, indicating that
Pitx2 directly binds miR-17-92 and miR-106b-25 chromatin dur-
ing embryogenesis (Fig. 1D). In addition, several miRs such as
miR-335 and miR-423 were up-regulated in Pitx2null mutant
hearts (Fig. 1A) and ChIP-Seq data suggest that they are also
potential direct Pitx2 target genes (Fig. S1 B and C).
mir-17-92 Expression Overlaps with Pitx2 Expression. To determine
the miR-17-92 expression pattern in heart, we generated an miR-
17-92 bacterial artificial chromosome transgenic LacZ reporter
line (20) and compared it with a Pitx2 LacZ knock-in allele (16).
In E12.5 hearts, LacZ staining indicated thatmiR-17-92 is expressed
in the outflow tract (OFT), left atrium (LA), coronary sinus, and
atrioventricular canal (Fig. S2 A–C), where Pitx2 is also endoge-
nously expressed (Fig. S2 D–F). Together, these data indicate that
miR-17-92 and Pitx2 have overlapping expression domains.
miR-17-92 and miR-106b-25 Mutant Mice Have Normal Baseline
Electrophysiological Parameters. We analyzed baseline cardiac
electrophysiological parameters of miR-17-92 and miR-106b-25
deficient adult mice. Four genotypes including wild-type, miR-
17-92null/+, miR-106b-25null/+, and miR-106b-25null/null mice were
studied. Only miR-17-92null/+ adult mice were compared in the
study because miR-17-92null/null mutants are embryonic lethal.
For each genotype, we evaluated heart rate (HR), the interval
from the beginning of the P wave to the peak of the R wave
(PR), the duration of the interval between the beginning of the Q
wave to the peak of the S wave (QRS), the duration of the Q-T
interval corrected for the heart rate atrial effective refractory
period (QTc), the sinus node recovery time (SNRT), atrial ef-
fective refractory period (AERP), and the atrioventricular nodal
effective refractory period (AVERP) (Table S1).
All baseline electrophysiologic parameters were similar in
miR-17-92null/+, miR-106b-25null/+, and miR-106b-25null/null mice
compared with wild-type mice. There were no episodes of spon-
taneous AF observed in any studied mice.
miR-17-92 and miR-106b-25 Deficient Mice Are Susceptible to Pacing-
Induced Atrial Fibrillation. To evaluate whether the loss of miR-17-92
and miR-106b-25 increases susceptibility to AF initiation, we
performed intracardiac electrical stimulation studies. An over-
driving pacing protocol was used to induce AF, and three pacing
trials were applied in each mouse. Simultaneous surface ECG
and intracardiac electrograms revealed absent P-waves and ir-
regular R-wave to R-wave (RR) intervals inmiR-17-92 null/+ (Fig.
2B) and miR-106b-25null/null (Fig. 2D) mice after burst pacing,
which are suggestive of AF. In contrast, wild-type (Fig. 2A) and
miR-106b-25null/+ (Fig. 2C) mice showed sinus rhythm instead of
reproducible AF following rapid pacing.
MiR-17-92 null/+ and miR-106b-25null/null showed a much higher
incidence of reproducible pacing-induced AF: 57.4% of miR-17-
92 null/+ mice (4 of 7) and 83.3% of miR-106b-25null/null mice (5 of
6) had reproducible pacing-induced AF after atrial pacing
whereas 14.3% of miR-106b-25null/+ (1 of 8) and no wild-type
(0 of 8) exhibited reproducible AF (Fig. 2E). Moreover, we
quantified the duration of the longest AF episode in each tested
animal and compared the differences between different geno-
types. The miR-17-92 null/+ and miR-106b-25null/null mice also
developed significantly longer duration of inducible AF com-
pared with wild-type mice (Fig. 2F). Taken together, our findings
Fig. 1. Pitx2 positively regulates miR-17-92 and
miR-106b-25. (A) Heat map of miR array with wild-
type control and Pitx2-null mutant hearts at E13.5.
Arrows designate individual miRs from mir-17-92
and mir-106b-25. (B) Real-time PCR validation of
miR array data at E13.5. *P < 0.05. (C) Three-month-
old mouse whole-heart ChIP-Seq enrichment pro-
files (GSE50401) (18) for Pitx2-bound loci at up-
stream of miR-17-92 and miR-106b-25. The peaks
from different datasets including Pitx2 ChIP-
Seq, input track, P2 mouse heart p300 ChIP-Seq
(GSE32587) (19), and 8-wk-old heart DNase I Hy-
persensitive Site (HS) Seq (ENCODE), as well as
mammal conservation (cons) track, are aligned for
comparison. Locations of real-time PCR validation of
ChIP enrichment are indicated under datasets. For
Pitx2 ChIP-Seq, input, and P300 ChIP-Seq, the scale
indicates read count that was normalized to 10
million reads. For the DNase I HS track, we used
the ENCODE default scale. N, negative control; R1,
region1; R2, region 2. (D) In vivo real-time ChIP PCR
indicated that miR-17-92 and miR-106b-25 were
bound by Pitx2 in E13.5 mouse hearts.
9182 | www.pnas.org/cgi/doi/10.1073/pnas.1405411111 Wang et al.
indicate that loss of miR-17-92 and miR-106b-25, like Pitx2,
increases susceptibility to AF.
Sinoatrial-Node Dysfunction in Mice with miR-17-92 Cardiac-Specific
Knockout and miR-106b-25 Haploinsufficiency. To determine whether
compound mutants for miR-17-92 and miR-106b-25 develop atrial
arrhythmias, we conditionally inactivated miR-17-92 using the
Nkx2.5 Cre driver that directs cre activity in heart. Continuous
ambulatory ECGs were recorded using telemetry in mice aged
from 6 wk to 4 mo old. We first evaluated Nkx2.5Cre;miR-17-
92flox/flox adult mice and found that they all had prolonged PR
intervals or first-degree atrioventricular (AV) block (Fig. 3F, n =
6), which is an AF risk factor in the human population (1). Im-
portantly, long-term follow-up of patients in the Framingham
cohort found that prolonged PR interval commonly progressed
to more severe arrhythmias requiring pacemaker implantation
that included SAN dysfunction, high-grade AV block, and AF (1).
The Nkx2.5Cre;miR-17-92flox/flox;miR-106b-25null/null double mutant
mice were runted, for reasons that are under investigation and
could not be used for these studies. However, Nkx2.5Cre;miR-
17-92flox/flox;miR-106b-25null/+ (n = 10) mice developed SAN dys-
function, also called sick-sinus syndrome, which was revealed by
irregular sinus rhythm with low amplitude P waves and variable
ventricular response (Fig. 3B). SAN dysfunction, which frequently
coexists with AF in human patients (21), is a known AF risk factor
(22) and significantly associated with prolonged atrial fibrillatory
cycle length (23). Both 6-wk-old (n = 4) and 4-mo-old (n = 6)
Nkx2.5Cre;miR-17-92flox/flox;miR-106b-25null/+ mice had SAN dys-
function, with more frequent and longer arrhythmias in 4-mo-old
mice. Moreover, some 4-mo-old Nkx2.5Cre;miR-17-92flox/flox;miR-
106b-25null/+ mice had, in addition to SAN dysfunction, type 2
second-degree atrioventricular block (AV block) (3 out of 6)
(Fig. 3C). Together these data suggest that progressive removal
of miR-17-92 and miR-106b-25 complexes results in atrial arrhyth-
mias of increasing severity that in human patients are known AF
risk factors. Moreover, our findings support the hypothesis that
miR-17-92 and miR-106b-25 have overlapping functions in atrial
homeostasis. Notably, the Nkx2.5Cre;miR-17-92flox/flox;miR-106b-
25null/+ failed to develop sustained AF perhaps because of the
presence of the single allele of miR-106b-25.
Because it has been reported that aged Nkx2.5Cre mice have
background-dependent phenotypes including arrhythmias (24),
we performed a number of control experiments. Importantly,
SAN dysfunction was not observed in mice of other genotypes
including wild-type (6 wk old, n = 4) (Fig. 3A), Nkx2.5Cre (6 wk
old, n = 4; 4 mo old, n = 4) (Fig. 3D), miR-17-92flox/flox; miR-
106b-25null/+ (6 wk old, n = 4; 4 mo old, n = 4) (Fig. 3E), and
Nkx2.5Cre; miR-17-92flox/flox (6 wk old, n = 3; 4 mo old, n = 3)
(Fig. 3F). In addition, one 4-mo-old Nkx2.5Cre mice had prolonged
PR interval that is similar as detected in 6-wk-old Nkx2.5Cre; miR-
17-92flox/flox mice.
Normal Cardiac Structure in Mice with miR-17-92 Cardiac-Specific
Knockout and miR-106b-25 Haploinsufficiency. To examination
whether the cardiac arrhythmias in Nkx2.5Cre; miR-17-92flox/flox;
miR-106b-25null/+ mice were caused by cardiac structural abnor-
malities, we first did echocardiography to examine the cardiac
function of Nkx2.5Cre; miR-17-92flox/flox; miR-106b-25null/+ mutants
(n = 6) compared with miR-17-92flox/flox; miR-106b-25null/+ and
Nkx2.5Cre controls (miR-17-92flox/flox; miR-106b-25null/+, n = 4;
Nkx2.5Cre n = 3). Compared with control mice, no obvious
changes in cardiac contractile function, dimension and wall thick-
ness were found in Nkx2.5Cre; miR-17-92flox/flox; miR-106b-25null/+
mutant mice at the age of 4 mo (Fig. S3 and Table S2). We also
performed hematoxylin/eosin (H&E) staining in Nkx2.5Cre; miR-17-
92flox/flox; miR-106b-25null/+ mutants (n = 10) and miR-17-92flox/flox;
miR-106b-25null/+ control mice (n = 4) at the age of 4 mo. We didn’t
detect any obvious defect of cardiac structure in Nkx2.5Cre; miR-17-
92flox/flox; miR-106b-25null/+mutants (n = 10) compared withmiR-17-
92flox/flox; miR-106b-25null/+ controls (n = 4) (Fig. S4 A and B) except
for one mutant that had a small membranous ventricular septal
defect. There were no atrial septal defects and no evidence for
atrial enlargement in the Nkx2.5Cre; miR-17-92flox/flox; miR-106b-
25null/+ mutants either histologically or by measuring atrial
weights (Fig. S4 A, B, and J). These findings are consistent with
a recent report from Chen et al., who also didn’t find structure
changes in Nkx2.5Cre; miR-17-92flox/flox mutant mice (25).
Wheat germ agglutinin (WGA) staining data indicated that
there was no obvious change in cardiomyocyte cell size of
ventricular myocardium of Nkx2.5Cre; miR-17-92flox/flox; miR-
106b-25null/+ mutants (n = 3) compared with miR-17-92flox/flox;
miR-106b-25null/+ controls (n = 3) at 4 mo old (Fig. S4 C–E).
Notably, although Chen et al. found that 10-mo-old Nkx2.5Cre;
miR-17-92flox/flox mutant mice exhibited cardiomyocyte hy-
pertrophy (25), we did not detect such changes in younger
mice. Masson’s Trichrome staining was used to detect the
Fig. 2. MiR-17-92 and miR-106b-25 deficient mice are susceptible to atrial
fibrillation. Simultaneous recordings of simultaneous surface ECG (lead I)
and intracardiac electrograms in wild-type (wt) (A), miR-17-92 null/+ (miR-17-
92 het) (B), miR-106b-25 null/+ (miR-106b-25 het) (C), and miR-106b-25null/null
(miR-106b-25 homo) (D) mice after burst pacing. Absent P-waves and ir-
regular RR intervals suggest pacing-induced AF inmiR-17-92 het (B) andmiR-
106b-25 homo (D) mice. (E) The incidence of inducible AF in different gen-
otypes compared with wt mice are summarized in the bar graph. (F) The
duration of the longest inducible AF episode in different genotypes com-
pared with wt mice is summarized in the bar graph. *P < 0.05, **P < 0.01.
Fig. 3. Mice with miR-17-92 cardiac-specific knockout and miR-106b-25
haploinsufficiency have spontaneous arrhythmias. Continuous ambulatory
ECGs were recorded in mice using telemetry. Arrows designate measured PR
intervals. Continuous ambulatory ECGs indicated SAN dysfunction in a 6-wk-
old Nxk2.5Cre; miR-17-92flox/flox; miR-106b-25null/+ (miR-17-92 CKO miR-106b-
25 het) mouse (B) but not in WT mouse (A), Nxk2.5Cre (D) miR-17-92flox/flox;
miR-106b-25null/+ (E), and Nxk2.5Cre; miR-17-92flox/flox (F). Although no epi-
sode of SAN dysfunction was detected, Nxk2.5Cre; miR-17-92flox/flox showed
prolonged PR intervals. Four-month-old miR-17-92 CKO miR-106b-25 het
mice had not only SAN dysfunction, but also type 2 second-degree atrio-
ventricular block (an example shown in C). RR interval and PR interval
measurements are labeled, and arrows designate P waves.
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level of fibrosis, which revealed no significant difference between
Nkx2.5Cre; miR-17-92flox/flox; miR-106b-25null/+ mutants (n =
3) and miR-17-92flox/flox; miR-106b-25null/+ controls (n = 3)
(Fig. S4 F–I). Moreover, we evaluated the ratio of atrial weight
to body weight (AW/BW) in Nkx2.5Cre; miR-17-92flox/flox; miR-
106b-25null/+ mutants (n = 4) compared with miR-17-92flox/flox;
miR-106b-25null/+ and Nkx2.5Cre controls (Nkx2.5Cre, n = 3; miR-
17-92flox/flox; miR-106b-25null/+, n = 3) and found there was no
significant difference in AW/BW between mutants and controls
(Fig. S4J). Taken together, we conclude that there were no ob-
vious cardiac structural defects in all but one of the 4-mo-old
Nkx2.5Cre; miR-17-92flox/flox; miR-106b-25null/+ mutants.
miR-17-92 Represses Shox2 and Tbx3. The short stature homeobox
gene Shox2 and T-Box gene Tbx3, SAN gene program components,
are required for normal SAN development (26, 27). Whole-mount
in situ hybridization followed by transverse sections through inflow
of the heart revealed that Shox2 expression is up-regulated in left
superior caval vein and coronary sinus of miR-17-92null/null mutants
(Fig. 4 A and B and Fig. S5 A and B). Immunofluorescence data
using a Shox2 antibody also indicated the up-regulation of Shox2
expression in miR-17-92null/null mutant left superior caval vein (Fig.
S5 I–L) compared with wild-type control (Fig. S5 E–H). Tbx3, that
enables SAN myocardium to separate from working atrial myo-
cardium is expanded and up-regulated in the left atrioventricular
canal of miR-17-92null/null mutant whereas Tbx3 expression is more
prominent in the right atrioventricular canal of wild-type con-
trols (Fig. 4 C and D and Fig. S5 C and D). To quantify the
expression level of Shox2 and Tbx3 in miR-17-92null/null mutants
compared with wild type, whole-heart total RNA were isolated
for quantitative RT-PCR (qRT-PCR). qRT-PCR data revealed
significant Shox2 and Tbx3 up-regulation in miR-17-92 mutants
compared with wild type (Fig. 4E).
miR-17-92 and miR-106b-25 Directly Regulate Shox2 and Tbx3. The
Shox2 3′ UTR contains conserved miR-17/20a/106b family seed
sequence (Fig. S6A), and the Tbx3 3′ UTR contains both a con-
served miR-17/20a/106b family seed site and a conserved miR-92a/
25 family seed site (Fig. S6 B and C). We constructed luciferase
reporter plasmids with the 3′ UTRs of Shox2 and Tbx3 to test
whether those miR seed sites function in vitro. There are drastic
reductions in luciferase activity for both Shox2 and Tbx3 luciferase
reporters when cotransfected with respective miR mimics (Fig. 4 F
and G and Fig. S6 D and E). When we mutate the respective miR
seed sites within the 3′ UTRs of Shox2 and Tbx3, the repression
caused by the corresponding miR is ablated (Fig. 4 F andG and Fig.
S6 D and E).
Given that Shox2 3′ UTR contains four conserved seed sites of
different miRs/miR families (Fig. S7A) and that only miR-17
family is expressed in the embryonic heart whereas the other
miRs/miR families are barely detectable (Fig. S7B), we hypoth-
esized that miR-17 family exerts the dominant miR regulation on
the Shox2 3′ UTR. To obtain genetic evidence supporting Shox2
regulation by miR-17 family, we generated a Shox2aHA knock-in
allele that replaced the endogenous 3′ UTR with a heterologous
3′ UTR to release Shox2 expression from endogenous miR
regulation. Notably the Shox2aHA allele still keeps the majority
of endogenous transcriptional regulatory sequences, including
intron 2 that contains a Pitx2 binding region (Fig. 4 H and I, Fig.
S8A, Methods, and SI Methods). Homozygous Shox2aHA mice
(Shox2aHA/HA) are neonatal lethal: 81.25% (13 out 16 from nine
litters) of Shox2aHA/HA mice die within postnatal day1 without
obvious morphological defects. To determine whether Shox2 ex-
pression is expanded in the Shox2aHA/HA embryos, we performed
immunofluorescence studies with a Shox2 antibody. At E16.5,
Shox2 is highly expressed in interatrial septum of Shox2aHA/HA
(Fig. 4 N–Q) but not in wild type (Fig. 4 J–M). Moreover, ex-
pression of Shox2 in SAN is dramatically higher in Shox2aHA/HA
(Fig. S8 D and E) compared with wild type (Fig. S8 B and C).
Although we cannot exclude the possibility that other features of
the Shox2HA allele, such as loss of splicing, may contribute to its
abnormal expression, our findings are consistent with Shox2 regu-
lation by miR-17-92.
In addition, we further performed in situ hybridization in
E12.5 miR-17-92null/null mutants and wild-type controls using
Bmp4 probe, which was previously shown as a downstream target
of Shox2 (28). The in situ hybridization and heart-sectioning data
indicated that Bmp4 expression is up-regulated inmiR-17-92null/null
mutants (Fig. S9 D–F) in a similar pattern of Shox2 up-regulation
in miR-17-92null/null mutants. Bmp4 is highly expressed in the left
superior caval vein and coronary sinus of miR-17-92null/null
mutants (Fig. S9 D–F) whereas it is only moderately expressed in
Fig. 4. MiR-17-92 directly represses Shox2 and Tbx3. (A–D) Whole-mount in
situ hybridization with indicated probes in embryonic mouse hearts. Black
arrows designate expression pattern. (E) qRT-PCR data indicate that ex-
pression of Shox2 and Tbx3 elevate in miR-17-92 knockout mutants. (F and
G) Luciferase reporter assays with reporters and miRs as labeled. Mean ±
SEM, *P < 0.05. (H) Schematic diagram of Shox2aHA allele. The mouse Shox2
gene contains six exons as indicated by numbered blocks (coding sequence
indicated in gray and noncoding sequence indicated in white). Partial of the
endogenous Shox2 sequence was replaced by DNA sequence encoding
N-terminal FLAG-HA-tagged, full-length Shox2a, IRES-DsRed, SV40 early polyA
signal and Frt flanking neomycin-resistance cassette driven by PGK promoter
(neo), which is named Shox2aHA/Neo allele. Neo is further removed by
crossing with germ-line Flp deleter strain to obtain Shox2aHA allele. (I) Long
range PCR showing targeted clones of Shox2aHA/Neo allele. Forward primer
on 5′ flanking region out of the 5′ homology arm and reverse primer on
DsRed yield a 7.2-kb band; forward primer on neo and reverse primer on 3′
flanking region out of 3′ homology arm yield a 3.6-kb band. (J–Q) Immu-
nofluorescence shows Shox2 is highly expressed in E16.5 atrial septum of
Shox2aHA/HA embryos but not in wild-type embryos. Boxed areas in J and N
are correspondingly shown at higher magnification in K–M and O–Q. Nuclei
(red) stained with DAPI. White arrows designate Shox2-expressing cells. ias,
interatrial septum; scv, surperior caval vein; vv, venous valve.
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the coronary sinus of wild-type controls (Fig. S9 A–C). Together,
these data further support the model that the miR-17-92 and
miR-106b-25 directly inhibit Shox2.
Discussion
The SAN develops from a larger pool of competent cells that is
progressively refined through the function of important de-
velopmental regulatory genes such as Pitx2. Progenitors within
the sinus venosus give rise to sinus horn myocardium and SAN
myocardium. In chick, discrete cells within lateral plate also
contribute to the pacemaker (29). Recent work indicates that
a dominant pacemaker activity is found in the E8.5 left inflow
tract, where Pitx2c is expressed, but switches to the right SAN by
E12.5 (15, 30). Our data are consistent with the notion that Pitx2
directly regulates this developmental switch in part by regulating
miR-17-92 and miR-106b-25.
Our findings indicate that miR-17-92 and miR-106b-25 directly
target SAN genes Shox2 and Tbx3. Previous studies have shown
that both Shox2 and Tbx3 promote SAN specification while
inhibiting working myocardium specification. Although Shox2 is
required for SAN development in mice, it has not yet been im-
plicated in human heart disease. However, there are data in-
dicating that Shox2 is a target for Tbx5 that has been implicated
in human AF and prolonged PR interval through GWAS studies
(31, 32). Tbx3 has also been implicated in human PR interval
prolongation in GWAS studies (32) and induces pacemaker
properties in adult myocardium when misexpressed (33). Other
than the novel targets we identified here, miR-17-92 and miR-
106b-25 have other targets. A transgenic mouse study using
conditional miR-17-92 overexpression suggested that miR-17-92
directly targets Pten and Cx43 (34). It will be necessary to in-
vestigate other miR-17-92 target genes to thoroughly understand
these two miR clusters in AF.
Mutations in miRs have not yet been uncovered in AF patients.
Before our study, genetic loss-of-function studies in mice have
failed to show a requirement for miRs in AF. A number of
profiling studies suggested potential roles for miRs in AF. For
example, miR-328 expression was elevated in human AF patients
and in a canine AF model although direct functional analysis of
miR-328 awaits further experimentation (35). MiR-21 expression
was increased in AF patients, a mouse model of spontaneous
AF, and age-induced atrial fibrosis whereas miR-21 knockdown
suppressed atrial fibrosis and AF promotion in rats (36, 37). A
recent report indicated that miR-29b plasma levels were de-
creased in patients with AF or congestive heart failure (38).
Similarly, miR-26 was down-regulated in the atria of an AF dog
model, and experimental miR-26 knockdown reproduced AF-
induced fibroblast activation, a central event in AF-promoting
remodeling (39). Expression of miR-26 family members was re-
duced in human AF patients, and Kcnj2 was shown to be a direct
miR-26 target. Moreover, miR-26 transcription was repressed by
nuclear factor of activated T cells making a direct connection
between calcium signaling and miR-26 in AF (40).
Experiments looking at miR-17-92 showed that miR-19a ex-
pression was reduced in serum of patients with persistent AF
(41). In patients with AF and mitral stenosis, several individual
members of the miR-17-92 cluster, including miR-17, miR-19a,
miR-19b, and miR-20a, were significantly down-regulated com-
pared with healthy individuals (42). Cardiac and smooth-muscle
conditional overexpression of miR-17-92 in mice developed di-
lated, hypertrophic cardiomyopathy with arrhythmias (34). Our
data along with the human expression data indicate that loss-of-
function of all miRs in the miR-17-92 cluster predisposes to AF,
suggesting that both loss and gain of miR-17-92 may stimulate
cardiac arrhythmias.
The Nkx2.5Cre;miR-17-92flox/flox mutant mice showed prolonged
PR interval whereas the Nkx2.5Cre;miR-17-92flox/flox;miR-106b-
25null/+ mutants had a more severe phenotype, including SAN
node dysfunction and second degree AV block, suggesting func-
tional redundancy between miR-17-92 and miR-106b-25. These
phenotypes are likely to be part of a continuous clinical spectrum
of conduction disorders in human patients. Data from the Fra-
mingham study have shown that many patients that initially
present with prolonged PR, also called first-degree AV block,
commonly progress to SAN dysfunction with higher-degree AV
block. These patients also commonly progress to atrial fibrilla-
tion (1). Moreover, a recent report revealed that miR-25 regu-
lates calcium handling by directly regulating Serca2 in adult heart
failure (43), suggesting thatmiR-17-92 andmiR-106b-25 function
in adult calcium homeostasis. Our data along with recent find-
ings suggest that miR-17-92 and miR-106b-25 have multiple gene
targets that function at different stages of AF predisposition.
Previous studies revealed that Pitx2 directly represses Shox2 in
left inflow tract working myocardium. We have now found that
this repressive mechanism also includes Shox2 repression by
Pitx2-regulated miRs miR-17-92 and miR-106b-25. Both Tbx3
and Shox2 expression domains were expanded in Pitx2 null/+ and
Pitx2 null/null mutant embryos. The working model that we pre-
viously developed (16) holds that Pitx2 functions within a gene
regulatory network (GRN) on the left side of the inflow tract
to directly repress Shox2 and the SAN genetic program in left
atrium and left caval veins.
Our results, indicating that Pitx2 directly transactivates miR-
17-92 and miR-106b-25 transcription, uncover a developmental
Pitx2-miR pathway that suppresses AF predisposition. The finding
that miR-17-92 and miR-106b-25 deficient mice are prone to AF
and directly repress the SAN regulatory genes Shox2 and Tbx3
further supports our model (Fig. S10). The notion that ectopic
expression of the SAN genetic program can contribute to AF
predisposition is an important area for future study. Moreover, it
is likely that this proposed developmental mechanism works
together with other mechanisms, such as defective calcium
handling, in AF predisposition. Although reduced Pitx2 levels
have been observed in some adult human AF patients, Pitx2 also
functions during development. In addition, recent findings in-
dicate that Pitx2 mRNA levels are elevated in some patients that
are in active AF at the time of tissue collection, indicating that
Pitx2 transcriptional regulation is complex and requires further
study (44). Because our work is limited to rodent studies, de-
finitive insight into the role of miR-17-92 and miR-106b-25 in
human AF await further human genetic studies.
Methods
See details in SI Methods.
Mouse Alleles and Transgenic Lines. The Pitx2Flag, miR-17-92–null, miR-17-92
Flox, miR-106b-25–null, and Nkx2.5Cre alleles were previously described (14,
24, 16). To generate the Shox2HA allele, which is free of endogenous 3′ UTR
regulation, we replaced part of the endogenous Shox2 sequence with a
Flag-HA-mouseShox2a-DsRed-polyA sequence that included an Frt flanked
neomycin-resistance cassette (Fig. 4E) in G4 embryonic stem (ES) cells (45).
G418 selected ES clones were screened by long-range PCR followed by se-
quencing of PCR products. Targeted clones showed a 7.2-kb band and a 3.6-kb
band on gel (Fig. 4F). Correctly targeted clone was injected into blastocysts to
create chimera mice. Chimeras were crossed with CD-1 females (Charles River) to
generate F1 mice and were subsequently genotyped by long-range PCR.
Chromatin Immunoprecipitation, ChIP-Sequencing, and ChIP-Seq Analysis.
E13.5 hearts were collected from Pitx2Flag allele and followed by ChIP
analysis as previously described (16), and DNA obtained from ChIP were
used for real-time PCR to quantify enrichment. ChIP-Seq was performed
using 3-mo-old mouse whole hearts of Pitx2Flag allele, and data are
available through the Gene Expression Omnibus (GEO) data repository
under accession number GSE50401 (18). For ChIP-Seq analysis, Ion tor-
rent PGM reads were aligned to the mm9 (NCBI Build 37) assembly using
Torrent Suite (2.0.1) Ion-alignment (2.0.3–1). A total 1.9 million reads
were uniquely mapped to mouse genome mm9. Total reads from input
were 1.29 × 107. ChIP-Seq peaks were called using Homer package using
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threshold FDR effective Poisson 3.7 × 10−8, minimum read number 5.
Then, 12,417 significant peaks were called; 8.97% of the reads were
enriched in significant peaks. The ChIP-Seq data were converted to
bedGraph file and visualized in the University of California, Santa Cruz
genome browser. The total read number was normalized to 10 million;
therefore, the y axis value indicated the normalized number of reads in
a 10-bp window. The Pitx2 ChIP-Seq dataset was also aligned to post-
natal day 2 (P2) mouse heart p300 ChIP-Seq (GSE32587) (19) and 8-wk-
old mouse heart DNase I Hypersensitive Site Seq (ENCODE) datasets to
show correlation.
Transthoracic Echocardiography. Mice were anesthetized using 1.5% (vol/vol)
isoflurane mixed with 95% (vol/vol) O2 and placed on a heated platform
where all four limbs were taped to copper ECG electrodes. Cardiac function
was assessed using a VisualSonics VeVo 770 Imaging System (VisualSonics)
equipped with a high-frequency 30-MHz probe, as described (46).
Cardiac Electrophysiology. In vivo electrophysiology in mice was conducted as
previously described (47). Briefly, intracardiac electrograms were recorded
using a 1.1F octapolar catheter (EPR-800; Millar Instruments) inserted via the
right jugular vein. Atrial fibrillation (AF) inducibility was determined by
previous protocol (48) and defined as overdriving pacing and defined as
the occurrence of rapid and fragmented atrial electrograms with irregular
AV-nodal conduction and ventricular rhythm for at least 1 s. Three pacing trials
were applied in each mouse. Inducibility of AF was considered positive if at least
two of three pacing trials induced AF. Moreover, ambulatory ECGs were recor-
ded in mice using telemetry transmitters (Data Sciences International) as pre-
viously described (49). Briefly, telemetry transmitters were implanted in the
abdominal cavity of mice with s.c. electrodes in a lead II configuration. ECGs were
continuously recorded by telemetry using Dataquest software, version 4.1 (Data
Sciences International) and analyzed using Dataquest software.
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